#United States #Camarillo #Meissner #CryoVault #TepoFlex

Introduction

In the complex world of biopharmaceutical manufacturing, the importance of effective freeze and thaw processes cannot be overstated. Meissner Corporation has positioned itself as a leader in this arena with the introduction of its dual platform options: the CryoVault® rigid container and the TepoFlex® flexible biocontainer. These innovative solutions not only enhance the security and integrity of sensitive biopharmaceuticals during storage and transport but also provide unparalleled flexibility for manufacturers at different scales.

The CryoVault® Rigid Container Platform

Launched to much acclaim, the CryoVault® system offers an industry-unique, robust solution that ensures the safe handling of biopharmaceuticals from initial fill to final dispense. With its durable ¼" HDPE construction, it protects biologics under various conditions, thereby minimizing degradation and preserving therapeutic efficacy. Since its debut in 2018, it has set a new standard for bulk drug substance freeze and thaw operations.

Key Features of CryoVault®

1. Unmatched Security: The design to withstand the rigors of deep freezing ensures the safe long-term storage of critical biological materials.
2. Modular Integration: CryoVault® integrates various components such as programmable freeze/thaw units, material handling systems, and secure shipping options, creating a seamless workflow.
3. Scalable Solutions: This system caters to diverse needs, accommodating everything from small-scale process development to large-scale commercial production.

The TepoFlex® Flexible Biocontainer Portfolio

Complementing the CryoVault® system is Meissner's TepoFlex® flexible biocontainer portfolio, which addresses the needs of manufacturers requiring versatile storage solutions. These biocontainers are crafted from a proven film that has been utilized for over 15 years, extending into freeze and thaw applications effectively.

Advantages of TepoFlex®

• - Adaptability: Available in sizes ranging from 50 mL to 10 L, these containers enable manufacturers to choose optimal solutions based on their specific processing volumes.
• - Integrity Assurance: The TepoFlex® design ensures that product integrity is maintained during freezing, transporting, and thawing, critical for the sensitive biopharmaceutical materials.
• - User-Friendly: The flexible format allows for easy handling and integration into existing processes, offering maximum convenience and efficiency.

Dual Solution for Diverse Needs

With both platforms, biopharmaceutical manufacturers are empowered to optimize their critical freeze and thaw unit operations in a variety of applications. The ability to choose between rigid and flexible solutions provides clients with the best fit for their operational needs, ultimately leading to improved safety and efficiency in manufacturing processes.

Conclusion

Meissner Corporation’s commitment to innovation in biopharmaceutical manufacturing is exemplified by the introduction of these dual platform options. By integrating robust and flexible solutions, they not only enhance product integrity but also streamline operations, minimizing risks associated with freezing and thawing critical biopharmaceuticals.

For more detailed information on Meissner's offerings, potential customers can visit www.meissner.com for resources including FAQs, brochures, and qualifications regarding their innovative freeze and thaw solutions.